Thelansis

Hereditary Transthyretin-Mediated (Hattr) Amyloidosis With Polyneuropathy Market Outlook Thelansis’s “Hereditary Transthyretin-Mediated (Hattr) Amyloidosis With Polyneuropathy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hereditary Transthyretin-Mediated (Hattr) Amyloidosis With Polyneuropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treat...

Hereditary Transthyretin-Mediated (Hattr) Amyloidosis With Polyneuropathy Market Outlook Thelansis’s “Hereditary Transthyretin-Mediated (Hattr) Amyloidosis With Polyneuropathy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hereditary Transthyretin-Mediated (Hattr) Amyloidosis With Polyneuropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Hereditary Transthyretin-Mediated (Hattr) Amyloidosis With Polyneuropathy Overview Hereditary transthyretin-mediated (hATTR) amyloidosis is a rare, fatal disease caused by transthyretin (TTR) gene mutations. These mutations lead to the buildup of amyloid proteins throughout the body, incl...

 Hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, previously known as familial amyloidotic polyneuropathy, is a rare genetic disorder caused by a mutation in the transthyretin (TTR) gene, which results in the production of abnormal TTR proteins that form amyloid fibrils. The disease is characterized by gradual and progressive degeneration of the autonomic and sensory-motor nervous systems and can be fatal. The symptoms of hATTR amyloidosis with polyneuropathy involve damage to the peripheral and autonomic nervous systems. Peripheral neuropathy usually begins with unusual sensations in the lower limbs, such as numbness, tingling, or burning. Autonomic neuropathy occurs when nerves that control vital functions, such as blood pressure, heart rate, sweating, bladder emptying, and digestion, are damaged. The sensory-motor polyneuropathy in hATTR amyloidosis with polyneuropathy progresses through three stages. In the initial stage, patients typically experience ...